INDICATION

EVENITY™ is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Read More

available osteoporosis therapy. The anabolic effect of EVENITY™ wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY™ use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered. Close

EVENITY™ VS TERIPARATIDE (STRUCTURE)

EVENITY™ vs teriparatide: BMD results1

BMD study after bisphosphonate use1

BMD data results are not meant to imply fracture efficacy and should not be extrapolated to predict differences in fracture efficacy.

EVENITY™ vs Teriparatide1 BMD – Mean of Months 6 and 12

TOTAL HIP (Primary)

Primary Hip

*P<0.0001.

EVENITY™ vs Teriparatide1 BMD at Month 6 and Month 12

LUMBAR SPINE

Lumbar Spine

* P<0.0001 vs baseline.

P<0.0001 vs teriparatide.

TOTAL HIP

total hip

* P<0.0001 vs baseline.

P<0.0001 vs teriparatide.

P<0.05 vs baseline.

FEMORAL NECK

femoral neck

* P<0.0001 vs baseline.

P<0.0001 vs teriparatide.

P<0.05 vs baseline.

EVENITY™ VS ALENDRONATE EFFICACY EVENITY™ VS PLACEBO EFFICACY

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH
EVENITY™ may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY™ should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY™ should be discontinued.

Back to Top

References: 1. Langdahl BL, Libanati C, Crittenden DB, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390:1585-1594.